Primarily, RET-altered NSCLC were treated by drugs targeting multiple alterations (Cabozantinib, Lenvatinib, RXDX-105, etc.)[32,33,34], resulting in a modest responses and poor tolerability due to off-targeted activity. The gene discussed is RET; the disease is non-small cell lung carcinoma.